Advanced In Vitro Models for Preclinical Drug Safety: Recent Progress and Prospects DOI Creative Commons

Dileep G. Nair,

Ralf Weiskirchen

Current Issues in Molecular Biology, Journal Year: 2024, Volume and Issue: 47(1), P. 7 - 7

Published: Dec. 26, 2024

The majority of drugs are typically orally administered. journey from drug discovery to approval is often long and expensive, involving multiple stages. A major challenge in the development process drug-induced liver injury (DILI), a condition that affects liver, organ responsible for metabolizing most drugs. Traditionally, identifying DILI risk has been difficult due poor correlation between preclinical animal models vitro systems. Differences physiology humans animals or cell lines contribute failure many programs during clinical trials. use advanced systems closely mimic human physiology, such as organ-on-a-chip like gut-liver-on-a-chip, can be crucial improving efficacy while minimizing toxicity. Additionally, adaptation these technologies potential significantly reduce both time cost associated with obtaining safe approvals, all adhering 3Rs principle (replacement, reduction, refinement). In this review, we discuss significance, current status, future prospects platforms, specifically models, supporting discovery.

Language: Английский

Developing 3D bioprinting for organs-on-chips DOI
Zhuhao Wu, Rui Liu, Ning Shao

et al.

Lab on a Chip, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Organs-on-chips (OoCs) can be directly fabricated by 3D bioprinting techniques, which enhance the structural and functional fidelity of organ models broaden applications OoCs.

Language: Английский

Citations

1
Harnessing Intelligence from Brain Cells In Vitro DOI Creative Commons
Brett J. Kagan, Forough Habibollahi, Bradley Watmuff

et al.

The Neuroscientist, Journal Year: 2025, Volume and Issue: unknown

Published: March 13, 2025

Harnessing intelligence from brain cells in vitro requires a multidisciplinary approach integrating wetware, hardware, and software. Wetware comprises the themselves, where differentiation induced pluripotent stem offers ethical scalability; hardware typically involves life support system setup to record activity deliver stimulation cells; software is required control process signals coming going cells. This review provides broad summary of foundational technologies underpinning these components, along with outlining importance technology integration. Of particular that this new ability extend beyond traditional methods assess primarily survival spontaneous neural cultures. Instead, focus returns core function tissue: neurocomputational information respond accordingly. Therefore, also covers work that, despite relatively early state current technology, has provided novel meaningful understandings field neuroscience opening exciting avenues for future research.

Language: Английский

Citations

1
Human-based complex in vitro models: their promise and potential for rare disease therapeutics DOI Creative Commons
Surat Parvatam, Francesca Pistollato, Lindsay J. Marshall

et al.

Frontiers in Cell and Developmental Biology, Journal Year: 2025, Volume and Issue: 13

Published: Jan. 27, 2025

Rare diseases affect a small percentage of an individual country’s population; however, with over 7,000 in total, rare represent significant disease burden impacting up to 10% the world’s population. Despite this, there are no approved treatments for almost 95% diseases, and existing cost-intensive patients. More than 70% genetic nature, patient-specific mutations. This calls need have personalised preclinical models that can lead effective, speedy, affordable therapeutic options. Complex vitro (CIVMs), including those using induced pluripotent stem cells (iPSCs), organoids, organs-on-chips emerging as powerful human-based pre-clinical systems capacity provide efficacy data enabling drugs move into clinical trials. In this narrative review, we discuss how CIVMs providing insights biomedical research on diseases. We also these being used trials develop Finally, propose recommendations human relevant could be leveraged increase translatability basic, applied nonclinical outcomes field therapeutics developed well middle-and low-income countries.

Language: Английский

Citations

0
Drugs and cellular dynamics in tumor microenvironment using microphysiological systems DOI
Yuji Nashimoto

Folia Pharmacologica Japonica, Journal Year: 2025, Volume and Issue: 160(2), P. 97 - 101

Published: Feb. 28, 2025

がん周囲の微小環境は,がん微小環境(tumor microenvironment:TME)と呼ばれ,免疫細胞やがん関連線維芽細胞,さらには血管内皮細胞やペリサイトなどが含まれる.かつて,これらの非がん細胞は,がんの疾患においては傍観者と思われてきたが,これらの細胞や分泌される分子群が,がんの進行において重要な役割を果たすことが明らかになってきた.TMEの複雑性を紐解き,その機序を明らかとするために,生体模倣システム(microphysiological system:MPS)が注目されている.MPSは「ヒトまたは動物由来の特定の組織の特徴を生体外でモデリングするための微小スケールの細胞培養プラットフォーム」と定義され,TMEの化学的または物理的な条件を制御し,がん細胞,がん周囲の細胞の応答を分析可能である.近年,がんのMPSに脈管系を組み込む技術が進展し,これによりTME内での物質や細胞の動態をより正確に評価できるようになってきている.本稿では,脈管系を含む最新のがんのMPSの研究報告と,TMEの物質・細胞動態の研究成果に関して概説する.

Citations

0
Advancements of paper-based microfluidics and organ-on-a-chip models in cosmetics hazards DOI Creative Commons
Sanidhya Pai,

A Binu,

G. S. Lavanya

et al.

RSC Advances, Journal Year: 2025, Volume and Issue: 15(13), P. 10319 - 10335

Published: Jan. 1, 2025

Different detection approaches for monitoring adulterants/hazards present in cosmetics using paper-based devices and organ-on-a-chip.

Language: Английский

Citations

0
3D cell culture models: how to obtain and characterize the main models DOI Creative Commons

M.M. Abdurakhmanova,

Anastasiia Leonteva,

N. S. Vasilieva

et al.

Vavilov Journal of Genetics and Breeding, Journal Year: 2025, Volume and Issue: 29(2), P. 175 - 188

Published: April 10, 2025

For many years, the gold standard in study of malignant tumors has been vitro culture tumor cells, vivo xenografts or genetically modified animal models. Meanwhile, three-dimensional cell models (3D cultures) have added to arsenal modern biomedical research. 3D cultures reproduce tissue-specific features tissue topology. This makes them relevant terms differentiation, metabolism and development drug resistance. Such are already being used by research groups for both basic translational research, may substantially reduce number studies, example field oncological In current literature, classified according technique their formation (with without a scaffold), cultivation conditions (static dynamic), as well cellular organization function. organization, divided into “spheroid models”, “organoids”, “organs-ona-chip” “microtissues”. Each these its own unique features, which should be taken account when using particular model an experiment. The simplest spheroid floating spherical aggregates. An organoid is more complex model, self-organizing structure formed from stem cells (SCs) capable self-renewal differentiation within model. Organ-on-a-chip chips microfluidic systems that simulate dynamic physical biological processes found organs tissues . By combining different types single structure, spheroids organoids can act basis microtissue – hybrid imitating specific phenotype containing tissuespecific extracellular matrix (ECM) components. review presents brief history culture. It describes main characteristics perspectives use “organ-on-a-chip” “microtissues” immune oncology solid tumors.

Language: Английский

Citations

0
Advanced In Vitro Models for Preclinical Drug Safety: Recent Progress and Prospects DOI Creative Commons

Dileep G. Nair,

Ralf Weiskirchen

Current Issues in Molecular Biology, Journal Year: 2024, Volume and Issue: 47(1), P. 7 - 7

Published: Dec. 26, 2024

The majority of drugs are typically orally administered. journey from drug discovery to approval is often long and expensive, involving multiple stages. A major challenge in the development process drug-induced liver injury (DILI), a condition that affects liver, organ responsible for metabolizing most drugs. Traditionally, identifying DILI risk has been difficult due poor correlation between preclinical animal models vitro systems. Differences physiology humans animals or cell lines contribute failure many programs during clinical trials. use advanced systems closely mimic human physiology, such as organ-on-a-chip like gut-liver-on-a-chip, can be crucial improving efficacy while minimizing toxicity. Additionally, adaptation these technologies potential significantly reduce both time cost associated with obtaining safe approvals, all adhering 3Rs principle (replacement, reduction, refinement). In this review, we discuss significance, current status, future prospects platforms, specifically models, supporting discovery.

Language: Английский

Citations

3